{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T20:12:10Z","timestamp":1775765530934,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2003,11,1]],"date-time":"2003-11-01T00:00:00Z","timestamp":1067644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2003,11]]},"DOI":"10.1016\/j.ijpharm.2003.08.002","type":"journal-article","created":{"date-parts":[[2003,10,9]],"date-time":"2003-10-09T04:36:33Z","timestamp":1065674193000},"page":"101-112","source":"Crossref","is-referenced-by-count":47,"title":["Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS\u00ae), with commercial lipid-based formulations"],"prefix":"10.1016","volume":"267","author":[{"given":"Hiroshi","family":"Fukui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Saheki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Sonoke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Tomii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junzo","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2003.08.002_BIB1","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of AmBisome\u00ae, a unilamellar liposomal formulation of amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB3","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/AAC.13.2.271","article-title":"Amphotericin B pharmacokinetics in humans","volume":"13","author":"Atkinson","year":"1978","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/infdis\/167.5.1247","article-title":"Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980\u20131990","volume":"167","author":"Beck-Sagu\u00e9","year":"1993","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB5","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1023\/A:1018997730462","article-title":"Safety and toxicokinetics of intravenous liposomal amphotericin B (AmBisome\u00ae) in beagle dogs","volume":"16","author":"Bekersky","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1461-5347(99)00160-1","article-title":"Lipid-based amphotericin B formulations: from animals to man","volume":"2","author":"Bekersky","year":"1999","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB7","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1128\/AAC.46.3.828-833.2002","article-title":"Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1128\/AAC.41.5.886","article-title":"Behavior of amphotericin B lipid complex in plasma in vitro and in the circulation of rats","volume":"41","author":"Bhamra","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0304-4157(86)90002-X","article-title":"How do the polyene macrolide antibiotics affect the cellular membrane properties?","volume":"864","author":"Bolard","year":"1986","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/AAC.42.2.263","article-title":"Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats","volume":"42","author":"Boswell","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB11","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/j.1552-4604.1998.tb04464.x","article-title":"AmBisome (liposomal amphotericin B): a comparative review","volume":"38","author":"Boswell","year":"1998","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB12","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1093\/jac\/44.3.397","article-title":"In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole","volume":"44","author":"Carrillo-Mu\u00f1oz","year":"1999","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB13","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1128\/AAC.35.6.1208","article-title":"Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats","volume":"35","author":"Fielding","year":"1991","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0378-5173(03)00404-6","article-title":"A novel delivery system for amphotericin B with lipid nano-sphere (LNS\u00ae)","volume":"265","author":"Fukui","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB15","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0378-5173(03)00342-9","article-title":"Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS\u00ae)","volume":"263","author":"Fukui","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/clinids\/12.2.308","article-title":"Amphotericin B: 30 years of clinical experience","volume":"12","author":"Gallis","year":"1990","journal-title":"Rev. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0378-5173(91)90249-N","article-title":"Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs","volume":"75","author":"Guo","year":"1991","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3109\/08982109809039931","article-title":"Lipid formulations of amphotericin B","volume":"8","author":"Hiemenz","year":"1998","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","article-title":"Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B","volume":"24","author":"Hillery","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB20","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1073\/pnas.85.16.6122","article-title":"Unusual lipid structures selectively reduce the toxicity of amphotericin B","volume":"85","author":"Janoff","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2911(08)60303-3","article-title":"Mode of action of clinically important antifungal drugs","volume":"27","author":"Kerridge","year":"1986","journal-title":"Adv. Microb. Physiol."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/j.2042-7158.1991.tb03189.x","article-title":"Tissue distribution of amphotericin B lipid complex in laboratory animals","volume":"43","author":"Olsen","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB23","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.43.3.471","article-title":"In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus","volume":"43","author":"Otsubo","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0168-3659(94)90212-7","article-title":"Lipid nano-sphere (LNS), a protein-free analogue of lipoproteins, as a novel drug carrier for parenteral administration IV","volume":"28","author":"Seki","year":"1994","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.bb.09.060180.002343","article-title":"Comparative properties and methods of preparation of lipid vesicles (liposomes)","volume":"9","author":"Szoka","year":"1980","journal-title":"Annu. Rev. Biophys. Bioeng."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/jac\/35.4.509","article-title":"Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans","volume":"35","author":"van Etten","year":"1995","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB27","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/BF01962595","article-title":"Treatment of systemic fungal infections: recent progress and current problems","volume":"7","author":"Walsh","year":"1988","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1023\/A:1016243313027","article-title":"Comparative tissue distribution and elimination of amphotericin B colloidal dispersion (Amphocil\u00ae) and Fungizone\u00ae after repeated dosing in rats","volume":"12","author":"Wang","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpharm.2003.08.002_BIB29","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1128\/JCM.37.6.1732-1738.1999","article-title":"Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan","volume":"37","author":"Yamazaki","year":"1999","journal-title":"J. Clin. Microbiol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517303004332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517303004332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T19:06:02Z","timestamp":1623438362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517303004332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11]]},"references-count":29,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2003,11]]}},"alternative-id":["S0378517303004332"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2003.08.002","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2003,11]]}}}